• API

    20 plus years of expertise in developing APIs. Recognised for rich chemistry experience, quality, manufacturing capabilities, regulatory and IP capabilities

    Read more

  • Formulations

    One of the world leaders in developing & manufacturing branded/non-branded generics. More than 200 marketed products and 150 ANDAs filed across most therapeutic areas.

    Read more

  • ARV

    One of the world’s largest global producer of anti-retroviral drugs. Over 30 US FDA and WHO PQ approved ARV molecules and combinations in ARV portfolio.

    Read more

  • Biosimilars

    Our Biosimilar program focuses on development, manufacturing and commercialization of high value complex biosimilars including monoclonal antibodies.

    Read more

News & Events

  • 02 Jul 2016
  • Hetero launches Biosimilar Bevacizumab
  • Hetero, one of India's leading generic pharmaceutical companies, today announces the launch of Biosimilar 'Bevacizumab' in India for the treatment of metastatic colorectal cancer (mCRC) under the brand name 'CizumabTM' Read more
  • 16 Dec 2015
  • Correct trademark name of Ledipasvir-Sofosbuvir is 'Ledifos'
  • This is with reference to the press release dated 9th December 2015 on the DCGI approval for Ledipasvir-Sofosbuvir. Hetero would like to clarify that there was an error in the brand name of the fixed-dose combination drug 'Ledipasvir-Sofosbuvir'. It was published as Ledisof. Read more